Background and aims Repository corticotropin injection (RCI; H.P. Acthar Gel) is a porcine pituitary-derived ACTH preparation approved by the FDA for therapy in selected cases of SLE. Previous studies have shown that RCI directly inhibits human B cell function in vitro.
Methods We used RNA-Seq to identify elements of the transcriptome that are acutely modulated by RCI in human B cells activated in vitro by IL4 and CD40 ligand. We compared RCI effects to those of a synthetic glucocorticoid (dexamethasone; Dex) under the same conditions.
Results 115 unique gene transcripts were significantly and reproducibly upregulated by RCI after 24 hours in culture. Pathways analysis revealed that upregulated genes were over-represented in “immune system response” (2.8-fold; p=0.026) and “response to stress” (4.16-fold; p=0.0069). 74 gene transcripts were down-regulated by RCI, and these were over-represented in two pathways: “immune system response” (2.91-fold; p=0.035) and “cellular process” (1.73-fold; p=0.0036). In Dex-treated cells, 65 gene transcripts were upregulated and 23 gene transcripts were down-regulated. There was no overlap between the set of genes upregulated by RCI and Dex. Two genes (PARM1 and RANKL) were downregulated by both RCI and Dex. Pathways analysis of Dex- treated samples did not reveal significant overrepresentation of regulated genes in any specific ontologic pathway.
Conclusions These data suggest that RCI exerts direct effects on human B cells to acutely modulate gene expression. These effects are distinct from those of glucocorticoids, supporting potential differences in mechanism of action of these two agents for treatment of autoimmune diseases.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.